Literature DB >> 19850658

Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX).

P I Burgos1, L M Vilá, J D Reveille, G S Alarcón.   

Abstract

To determine the factors associated with peripheral vascular damage in systemic lupus erythematosus patients and its impact on survival from Lupus in Minorities, Nature versus Nurture, a longitudinal US multi-ethnic cohort. Peripheral vascular damage was defined by the Systemic Lupus International Collaborating Clinics Damage Index (SDI). Factors associated with peripheral vascular damage were examined by univariable and multi-variable logistic regression models and its impact on survival by a Cox multi-variable regression. Thirty-four (5.3%) of 637 patients (90% women, mean [SD] age 36.5 [12.6] [16-87] years) developed peripheral vascular damage. Age and the SDI (without peripheral vascular damage) were statistically significant (odds ratio [OR] = 1.05, 95% confidence interval [CI] 1.01-1.08; P = 0.0107 and OR = 1.30, 95% CI 0.09-1.56; P = 0.0043, respectively) in multi-variable analyses. Azathioprine, warfarin and statins were also statistically significant, and glucocorticoid use was borderline statistically significant (OR = 1.03, 95% CI 0.10-1.06; P = 0.0975). In the survival analysis, peripheral vascular damage was independently associated with a diminished survival (hazard ratio = 2.36; 95% CI 1.07-5.19; P = 0.0334). In short, age was independently associated with peripheral vascular damage, but so was the presence of damage in other organs (ocular, neuropsychiatric, renal, cardiovascular, pulmonary, musculoskeletal and integument) and some medications (probably reflecting more severe disease). Peripheral vascular damage also negatively affected survival.

Entities:  

Mesh:

Year:  2009        PMID: 19850658      PMCID: PMC3758688          DOI: 10.1177/0961203309105877

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  16 in total

1.  Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors.

Authors:  Murray B Urowitz; Dominique Ibañez; Dafna D Gladman
Journal:  J Rheumatol       Date:  2006-11-15       Impact factor: 4.666

Review 2.  Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?

Authors:  Ian N Bruce
Journal:  Best Pract Res Clin Rheumatol       Date:  2005-10       Impact factor: 4.098

3.  Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration.

Authors:  A Zonana-Nacach; A Camargo-Coronel; P Yáñez; M de Lourdes Sánchez; F J Jímenez-Balderas; J Aceves-Avila; P Martínez-Osuna; J Fuentes; F Medina; A Fraga
Journal:  Lupus       Date:  1998       Impact factor: 2.911

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

5.  The bimodal mortality pattern of systemic lupus erythematosus.

Authors:  M B Urowitz; A A Bookman; B E Koehler; D A Gordon; H A Smythe; M A Ogryzlo
Journal:  Am J Med       Date:  1976-02       Impact factor: 4.965

6.  The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus.

Authors:  D D Gladman; M B Urowitz; C H Goldsmith; P Fortin; E Ginzler; C Gordon; J G Hanly; D A Isenberg; K Kalunian; O Nived; M Petri; J Sanchez-Guerrero; M Snaith; G Sturfelt
Journal:  Arthritis Rheum       Date:  1997-05

7.  Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture.

Authors:  G S Alarcón; A W Friedman; K V Straaton; J M Moulds; J Lisse; H M Bastian; G McGwin; A A Bartolucci; J M Roseman; J D Reveille
Journal:  Lupus       Date:  1999       Impact factor: 2.911

8.  Mortality in systemic lupus erythematosus.

Authors:  S Bernatsky; J-F Boivin; L Joseph; S Manzi; E Ginzler; D D Gladman; M Urowitz; P R Fortin; M Petri; S Barr; C Gordon; S-C Bae; D Isenberg; A Zoma; C Aranow; M-A Dooley; O Nived; G Sturfelt; K Steinsson; G Alarcón; J-L Senécal; M Zummer; J Hanly; S Ensworth; J Pope; S Edworthy; A Rahman; J Sibley; H El-Gabalawy; T McCarthy; Y St Pierre; A Clarke; R Ramsey-Goldman
Journal:  Arthritis Rheum       Date:  2006-08

9.  Vascular manifestations of systemic lupus erythematosus.

Authors:  A Ansari; P H Larson; H D Bates
Journal:  Angiology       Date:  1986-06       Impact factor: 3.619

10.  Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture.

Authors:  J D Reveille; J M Moulds; C Ahn; A W Friedman; B Baethge; J Roseman; K V Straaton; G S Alarcón
Journal:  Arthritis Rheum       Date:  1998-07
View more
  10 in total

1.  Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus.

Authors:  Xiao-Yang Wang; Xue-Qing Tang; Ya-Juan Huang; Wei-Ying Chen; Xue-Qing Yu
Journal:  Clin Rheumatol       Date:  2011-12-23       Impact factor: 2.980

Review 2.  Cardiovascular Implications of Immune Disorders in Women.

Authors:  Caitlin A Moran; Lauren F Collins; Nour Beydoun; Puja K Mehta; Yetunde Fatade; Ijeoma Isiadinso; Tené T Lewis; Brittany Weber; Jill Goldstein; Igho Ofotokun; Arshed Quyyumi; May Y Choi; Kehmia Titanji; Cecile D Lahiri
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 23.213

Review 3.  To what extent can preventive treatments prevent damage from systemic lupus erythematosus?

Authors:  Elena M Massarotti; Peter H Schur
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.686

4.  Phenome-wide association study identifies marked increased in burden of comorbidities in African Americans with systemic lupus erythematosus.

Authors:  April Barnado; Robert J Carroll; Carolyn Casey; Lee Wheless; Joshua C Denny; Leslie J Crofford
Journal:  Arthritis Res Ther       Date:  2018-04-10       Impact factor: 5.156

Review 5.  Systemic Lupus Erythematosus and Cardiovascular Disease.

Authors:  Surajkumar B Jha; Ana P Rivera; Gabriela Vanessa Flores Monar; Hamza Islam; Sri Madhurima Puttagunta; Rabia Islam; Sumana Kundu; Ibrahim Sange
Journal:  Cureus       Date:  2022-02-08

6.  Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications.

Authors:  May Y Choi; Daniel Li; Candace H Feldman; Kazuki Yoshida; Hongshu Guan; Seoyoung C Kim; Brendan M Everett; Karen H Costenbader
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

7.  Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry.

Authors:  Antonio Fernández-Nebro; Íñigo Rúa-Figueroa; Francisco J López-Longo; María Galindo-Izquierdo; Jaime Calvo-Alén; Alejandro Olivé-Marqués; Carmen Ordóñez-Cañizares; María A Martín-Martínez; Ricardo Blanco; Rafael Melero-González; Jesús Ibáñez-Rúan; José Antonio Bernal-Vidal; Eva Tomero-Muriel; Esther Uriarte-Isacelaya; Loreto Horcada-Rubio; Mercedes Freire-González; Javier Narváez; Alina L Boteanu; Gregorio Santos-Soler; José L Andreu; José M Pego-Reigosa
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.817

Review 8.  Cardiovascular involvement in autoimmune diseases.

Authors:  Jenny Amaya-Amaya; Laura Montoya-Sánchez; Adriana Rojas-Villarraga
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

9.  Predisposing factors to nonfatal cardiovascular events in women with systemic lupus erythematosus. An observational, cross-sectional, multicenter study in Spain from the risk/systemic lupus erythematosus thematic network.

Authors:  Mar Fernández-Garcés; Gonzalo Haro; María Luisa Micó
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

10.  Risk of Peripheral Arterial Occlusive Disease in Patients With Systemic Lupus Erythematosus: A Nationwide Population-Based Cohort Study.

Authors:  Ya-Wen Chuang; Mei-Ching Yu; Cheng-Li Lin; Tung-Min Yu; Kuo-Hsiung Shu; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.